Pre-market trend | Asymchem (6821.HK) shows bullish signs with reduced volume consolidation on 4/29, can the CXO sector recover?

Today, Asymchem's trading volume was approximately HKD 105 million, with overall trading being relatively light. However, bullish signals have begun to emerge on the daily MACD level, suggesting that the short-selling pressure accumulated during the previous continuous pullback is starting to weaken marginally. Asymchem's stock price has been fluctuating in the low range recently, with short-term moving averages tending to flatten, and the balance of bullish and bearish forces is gradually stabilizing. The emergence of this bullish signal typically indicates that the market is brewing a directional choice, increasing the possibility of a phase bottom formation. On the news front, the recovery pace of the CXO industry is one of the current market focuses. Global investment in innovative drug research and development continues to grow, and the outsourcing demand from large multinational pharmaceutical companies is gradually warming up, providing support for orders to CDMO companies like Asymchem. However, the Federal Reserve's decision to maintain interest rates in April's FOMC meeting and its hawkish stance make it difficult for the global biopharmaceutical financing environment to significantly loosen in the short term, and the R&D outsourcing budgets of early biotech companies may continue to be suppressed. In terms of sectors, WuXi AppTec fell 3.7% today, and the weakness of the CXO sector leader has created some drag on sector sentiment. It remains to be seen whether Asymchem can independently rebound. From a technical perspective, Asymchem's current trading volume is low, and the HKD 105 million trading volume is insufficient to support a significant rebound. The reliability of bullish signals in a low-volume environment is relatively limited, and it will be necessary to observe whether there is a gentle increase in volume to accompany it. If the CXO sector leader stabilizes and rebounds first, Asymchem, as a quality target within the sector, is expected to benefit from a follow-on effect of funds